CN111603485A - Medicine formula for treating rhinitis and preparation method - Google Patents
Medicine formula for treating rhinitis and preparation method Download PDFInfo
- Publication number
- CN111603485A CN111603485A CN202010655685.9A CN202010655685A CN111603485A CN 111603485 A CN111603485 A CN 111603485A CN 202010655685 A CN202010655685 A CN 202010655685A CN 111603485 A CN111603485 A CN 111603485A
- Authority
- CN
- China
- Prior art keywords
- oil
- oxide powder
- zinc oxide
- borneol
- musk
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010039083 rhinitis Diseases 0.000 title claims abstract description 31
- 239000003814 drug Substances 0.000 title claims abstract description 28
- 238000002360 preparation method Methods 0.000 title abstract description 9
- 229940079593 drug Drugs 0.000 title description 9
- 239000003921 oil Substances 0.000 claims abstract description 24
- 235000019198 oils Nutrition 0.000 claims abstract description 24
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims abstract description 23
- 235000019483 Peanut oil Nutrition 0.000 claims abstract description 22
- 239000000312 peanut oil Substances 0.000 claims abstract description 22
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 20
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims abstract description 20
- 229940116229 borneol Drugs 0.000 claims abstract description 20
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims abstract description 20
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims abstract description 20
- 241000402754 Erythranthe moschata Species 0.000 claims abstract description 19
- 239000007923 nasal drop Substances 0.000 claims abstract description 10
- 238000003756 stirring Methods 0.000 claims abstract description 8
- LPEBYPDZMWMCLZ-CVBJKYQLSA-L zinc;(z)-octadec-9-enoate Chemical compound [Zn+2].CCCCCCCC\C=C/CCCCCCCC([O-])=O.CCCCCCCC\C=C/CCCCCCCC([O-])=O LPEBYPDZMWMCLZ-CVBJKYQLSA-L 0.000 claims abstract description 5
- 238000009924 canning Methods 0.000 claims abstract description 4
- 239000002994 raw material Substances 0.000 claims abstract description 4
- 238000000034 method Methods 0.000 claims description 8
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims description 5
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims description 5
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 claims description 3
- 239000002014 nasya oil Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- -1 zinc oxide powder Chemical compound 0.000 claims description 2
- 239000006196 drop Substances 0.000 claims 1
- 238000004806 packaging method and process Methods 0.000 claims 1
- 208000024891 symptom Diseases 0.000 abstract description 13
- 210000002850 nasal mucosa Anatomy 0.000 abstract description 10
- 230000008439 repair process Effects 0.000 abstract description 4
- 210000004877 mucosa Anatomy 0.000 abstract description 3
- 230000000694 effects Effects 0.000 description 8
- 210000003928 nasal cavity Anatomy 0.000 description 7
- 206010028748 Nasal obstruction Diseases 0.000 description 4
- 206010039101 Rhinorrhoea Diseases 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 208000010753 nasal discharge Diseases 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000001387 anti-histamine Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 210000001331 nose Anatomy 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 206010041232 sneezing Diseases 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010028735 Nasal congestion Diseases 0.000 description 2
- 206010039085 Rhinitis allergic Diseases 0.000 description 2
- 206010039509 Scab Diseases 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 201000010105 allergic rhinitis Diseases 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000004081 cilia Anatomy 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000013583 drug formulation Substances 0.000 description 2
- 239000000428 dust Substances 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 229940049964 oleate Drugs 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 201000008283 Atrophic Rhinitis Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000928504 Centipeda minima Species 0.000 description 1
- 206010013496 Disturbance in attention Diseases 0.000 description 1
- 241000521257 Hydrops Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010024642 Listless Diseases 0.000 description 1
- 241000218378 Magnolia Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 206010039088 Rhinitis atrophic Diseases 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 241001251949 Xanthium sibiricum Species 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229940124579 cold medicine Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000010808 liquid waste Substances 0.000 description 1
- 208000017971 listlessness Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000037321 sleepiness Effects 0.000 description 1
- 239000003998 snake venom Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002910 solid waste Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/55—Glands not provided for in groups A61K35/22 - A61K35/545, e.g. thyroids, parathyroids or pineal glands
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Otolaryngology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a medicine formula for treating rhinitis and a preparation method thereof, wherein the medicine formula is prepared from the following raw materials in parts by weight: 2 parts of borneol, 6 parts of zinc oxide powder, 1 part of peanut oil and 1 part of musk. The preparation method of the medicine formula comprises the following steps: adding zinc oxide powder into peanut oil, stirring to uniformly disperse the zinc oxide powder in the peanut oil to generate mixed oil, adding borneol and musk into the prepared mixed oil, fully stirring to uniformly disperse the borneol and the musk in the mixed oil to prepare the nasal drop oil, and bottling and canning under the condition that the components in the nasal drop oil are uniformly dispersed. According to the medicine formula for treating rhinitis and the preparation method, borneol and musk are combined to strengthen the orifice opening direction of traditional Chinese medicine for treating rhinitis, and zinc oxide powder and peanut oil react to generate zinc oleate, so that the medicine formula can repair and protect nasal mucosa, and further achieve the purposes of opening the orifice, protecting the mucosa and treating both symptoms and root causes.
Description
Technical Field
The invention relates to the technical field of medicines, in particular to a medicine formula for treating rhinitis and a preparation method thereof.
Background
In modern life, besides various solid or liquid wastes which can be seen by naked eyes, invisible gas and toxic and harmful tiny particles floating in the air become an increasingly important reason for rhinitis patients. The nasal cavity is a necessary channel for exchanging air between a human body and the outside, and under normal conditions, the nasal cavity regulates and controls the temperature and humidity of the inhaled air, and adheres and discharges solid particles in the air out of the body through mucous membranes and cilia in the nasal cavity. But the development of modern civilization has driven smaller and smaller particles; a large amount of toxic and harmful tiny particles can not be discharged by cilia of the nasal cavity, and are adhered to the mucosa of the nasal cavity for a long time to form infection or directly stimulate the body to form various inflammatory or allergic symptoms.
In the field of rhinitis treatment, western medicines mainly take antibiotics and antiallergic drugs, and traditional Chinese medicines and Chinese patent medicines mainly take orifice-opening drugs such as siberian cocklebur, biond magnolia flower, centipeda minima and the like. The corresponding treatment method can improve rhinitis symptoms such as running nose, nasal obstruction and the like, but the nasal mucosa can not be repaired, and the injury to the nasal mucosa is deepened once for each attack of the rhinitis, which is one of the reasons that the rhinitis repeatedly attacks and the attack frequency is higher and higher.
Disclosure of Invention
Aiming at the technical problems in the related art, the invention provides a medicine formula for treating rhinitis and a preparation method thereof, which can overcome the defects in the prior art.
In order to achieve the technical purpose, the technical scheme of the invention is realized as follows:
the medicine formula for treating rhinitis is prepared from the following raw materials in parts by weight:
2 parts of borneol,
6 parts of zinc oxide powder, namely zinc oxide powder,
1 part of peanut oil, namely 1 part of peanut oil,
musk 1 part.
According to another aspect of the present invention, there is provided a method of preparing a pharmaceutical formulation for the treatment of rhinitis, the method comprising the steps of:
s1, adding 6 parts of zinc oxide powder into 1 part of peanut oil by weight, and stirring to uniformly disperse the zinc oxide powder in the peanut oil to generate mixed oil;
s2, adding 2 parts of borneol and 1 part of musk into the mixed oil prepared in the step S1, and fully stirring to uniformly disperse the borneol and the musk into the mixed oil to prepare nasal drop oil;
s3, bottling and canning the components in the nasal drop oil in a uniformly dispersed state.
Further, the nasal oil is prepared and placed for no more than two hours to complete split charging.
Further, in step S1, the zinc oxide powder is fully contacted with the unsaturated fatty acid contained in the peanut oil to react.
Furthermore, the mixed oil contains zinc oleate salt and zinc stearate salt.
The formula principle is as follows:
the theory of traditional Chinese medicine: the function of borneol is mainly to induce resuscitation, refresh mind, clear heat and alleviate pain. The musk has the functions and main indications of inducing resuscitation and refreshing mind, activating blood and dredging channels, and relieving swelling and pain. The borneol and the musk are combined to strengthen the effect of opening orifices and inducing resuscitation, and can effectively improve the symptoms of nasal obstruction of rhinitis patients.
Modern research:
musk: in modern researches, musk has the effects of reducing blood pressure, increasing heart rate, resisting inflammation, having androgen-like effect, enhancing immunity, inhibiting platelet aggregation, resisting snake venom, histamine, tumors and the like. The anti-inflammatory and antihistamine effects of musk are mainly utilized in the formula, and various symptoms of nasal discharge, nasal obstruction, sneeze and the like of rhinitis patients are related to inflammatory symptoms of nasal mucosa; the antihistaminic effect is beneficial to improving uncomfortable symptoms caused by nasal mucosa allergy of patients with allergic rhinitis.
Borneol: in modern researches, borneol is mainly used for resisting bacteria and diminishing inflammation and promoting transdermal absorption of other medicines. The antibacterial and anti-inflammatory effects of the borneol in the formula improve various bacterial infections of rhinitis patients caused by the long-term inflammatory symptoms of nasal mucosa, and the borneol can effectively kill various bacteria such as staphylococcus aureus, beta hemolytic streptococcus, green streptococcus and the like.
Zinc oxide powder and peanut oil: the zinc oxide powder has the medicinal values of moisture absorption and convergence, and can improve wound surface hydrops and inflammatory symptoms caused by various reasons and protect the skin. In the formula, zinc oxide powder and unsaturated fatty acid in peanut oil generate oleate and stearate, so that the moisture absorption and convergence effects of the zinc oxide powder and the unsaturated fatty acid in peanut oil are maintained, the drug property is delayed, and the stimulation is reduced; can play the drug effect softly and durably at the damaged nasal mucosa, repair and protect the nasal mucosa.
The invention has the beneficial effects that: according to the medicine formula for treating rhinitis and the preparation method, borneol and musk are combined to strengthen the orifice opening direction of traditional Chinese medicine for treating rhinitis, and zinc oxide powder and peanut oil react to generate zinc oleate, so that the medicine formula can repair and protect nasal mucosa, and further achieve the purposes of opening the orifice, protecting the mucosa and treating both symptoms and root causes.
Detailed Description
The technical solutions in the embodiments of the present invention are clearly and completely described below, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all embodiments. All other embodiments that can be derived by one of ordinary skill in the art from the embodiments given herein are intended to be within the scope of the present invention.
Example 1
A medicine formula for treating rhinitis is prepared from the following raw materials: 2kg of borneol, 6kg of zinc oxide powder, 1kg of peanut oil and 1kg of musk.
The preparation method of the medicine prescription for treating rhinitis comprises the following steps:
s1, adding 6kg of zinc oxide powder into 1kg of peanut oil, stirring to uniformly disperse the zinc oxide powder in oil, and fully contacting with unsaturated fatty acid contained in the peanut oil to react to generate mixed oil containing zinc oleate and zinc stearate;
s2, adding 2kg of borneol and 1kg of musk into the prepared mixed oil, and fully stirring to uniformly disperse the added components into the prepared mixed oil to prepare the nasal drop oil;
and S3, bottling and canning the mixed components in the nasal drop oil in a uniformly dispersed state (the mixed components are placed for no more than two hours after the nasal drop oil is prepared).
The application method of the medicine prescription for treating the rhinitis provided by the embodiment of the invention comprises the following steps: after shaking up, the mixture is dripped into nasal cavity for three times a day or used when rhinitis occurs. Note that: it is forbidden for pregnant women.
Typical cases
Case one: women in 38 years old, company staff, rhinitis history for more than 10 years, manifested as intermittent nasal obstruction and discharge, and pus and thick nasal discharge in the affected period, which resulted in listlessness, poor concentration and hypomnesis. The chronic nasosinusitis is diagnosed in a hospital, and the effect is not obvious after the antibiotic and the rhinitis tablet are orally taken. After one week of use of the drug formulation for treating rhinitis described in example 1, the symptoms of nasal congestion are reduced, and after two weeks of use of the drug formulation for treating rhinitis described in example 1, the frequency of nasal congestion and nasal discharge is significantly reduced; the mental appearance is also restored to a normal state.
Case two: when the plum lady is 20 years old, students in schools can self-tell that dust is more in the space and air temperature changes greatly suddenly, sneezing can occur continuously, a large amount of water samples are obtained in nasal cavities, and the study and life of the students are seriously affected. Allergic rhinitis is diagnosed in hospitals, and patients can be immediately changed after taking certain allergic tablets (antihistamine medicines), but have clinical manifestations of palpitation, sleepiness, dry mouth and the like after taking the tablets. After continuously using the drug composition for treating rhinitis, which is described in example 1, for three weeks, the desensitizing effect to the dust space and the cold and hot alternating space is significant.
Case three: mr. Hu Sheng, age 40, government officers, patients mentioned above nasal secretion is in block form, difficult to blow, hard to pull out dry scab, small amount of nosebleed, continuous sneezing and flowing nose water when getting up in the morning, easy to stuffy nose when temperature difference is large, and symptoms are improved after eating certain cold granules. Atrophic rhinitis is diagnosed in hospitals, and the treatment is delayed because the symptoms are covered by taking cold medicines frequently when the patient suffers from the disease. Doctors recommend that conservative treatment is difficult to guarantee due to serious illness; anterior naris closure treatment may be considered. The patient selects a conservative treatment scheme, acts on a certain nasal drop and a certain mycin ointment, and has limited effect. After the medicine composition for treating rhinitis, which is described in the embodiment 1, is used, nasal secretion is obviously reduced, scab is easily blown out, and the frequency of continuous sneezing is reduced.
In conclusion, by means of the technical scheme, the borneol and the musk are combined to strengthen the orifice opening direction of the traditional Chinese medicine formula for treating rhinitis; in addition, the oleate generated by the zinc oxide powder and the peanut oil can repair and protect damaged nasal mucosa, and provides a choice for treating both principal and secondary aspects of diseases for patients.
The above description is only for the purpose of illustrating the preferred embodiments of the present invention and is not to be construed as limiting the invention, and any modifications, equivalents, improvements and the like that fall within the spirit and principle of the present invention are intended to be included therein.
Claims (5)
1. The medicine formula for treating rhinitis is characterized by being prepared from the following raw materials in parts by weight:
2 parts of borneol,
6 parts of zinc oxide powder, namely zinc oxide powder,
1 part of peanut oil, namely 1 part of peanut oil,
musk 1 part.
2. A method of preparing a pharmaceutical formulation according to claim 1, comprising the steps of:
s1, adding 6 parts of zinc oxide powder into 1 part of peanut oil by weight, and stirring to uniformly disperse the zinc oxide powder in the peanut oil to generate mixed oil;
s2, adding 2 parts of borneol and 1 part of musk into the mixed oil prepared in the step S1, and fully stirring to uniformly disperse the borneol and the musk into the mixed oil to prepare nasal drop oil;
s3, bottling and canning the components in the nasal drop oil in a uniformly dispersed state.
3. The method of claim 2, wherein the sub-packaging is accomplished no more than two hours after the nasal oil drops are prepared.
4. The method of claim 2, wherein the zinc oxide powder is reacted in step S1 by contacting with unsaturated fatty acid contained in peanut oil.
5. The method according to claim 4, wherein the mixed oil contains zinc oleate and zinc stearate.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010655685.9A CN111603485A (en) | 2020-07-09 | 2020-07-09 | Medicine formula for treating rhinitis and preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010655685.9A CN111603485A (en) | 2020-07-09 | 2020-07-09 | Medicine formula for treating rhinitis and preparation method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111603485A true CN111603485A (en) | 2020-09-01 |
Family
ID=72195517
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010655685.9A Pending CN111603485A (en) | 2020-07-09 | 2020-07-09 | Medicine formula for treating rhinitis and preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111603485A (en) |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010059063A (en) * | 2008-09-01 | 2010-03-18 | Earth Chem Corp Ltd | Repellent against house dust mite |
| JP2011213647A (en) * | 2010-03-31 | 2011-10-27 | Takasago Internatl Corp | Anti-allergic agent and flavor and aroma composition containing the same |
| CN102370857A (en) * | 2010-08-27 | 2012-03-14 | 翟长民 | Rhinitis treating paste |
| CN102648934A (en) * | 2011-02-24 | 2012-08-29 | 邴守兰 | Traditional Chinese medicine composition for treating chronic simple rhinitis and preparation method thereof |
| CN104840520A (en) * | 2015-03-30 | 2015-08-19 | 李志君 | Rhinitis oil formula and preparation technology thereof |
| CN104940727A (en) * | 2015-07-07 | 2015-09-30 | 王睿超 | Paste for treating rhinitis and preparation method thereof |
| WO2016019627A1 (en) * | 2014-08-08 | 2016-02-11 | Shenzhen Hightide Biopharmaceutical, Ltd. | Liquid formulation compositions, medicament delivery devices, and methods of preparation and use thereof |
| CN107569536A (en) * | 2017-09-22 | 2018-01-12 | 杨斌 | A kind of rhinitis paste and preparation method thereof |
| CN108096308A (en) * | 2018-01-23 | 2018-06-01 | 袁影丽 | A kind of drug for treating allergic rhinitis, preparation and preparation method thereof |
| CN110652544A (en) * | 2019-11-20 | 2020-01-07 | 吴波 | Pharmaceutical composition for treating rhinitis and preparation method thereof |
-
2020
- 2020-07-09 CN CN202010655685.9A patent/CN111603485A/en active Pending
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010059063A (en) * | 2008-09-01 | 2010-03-18 | Earth Chem Corp Ltd | Repellent against house dust mite |
| JP2011213647A (en) * | 2010-03-31 | 2011-10-27 | Takasago Internatl Corp | Anti-allergic agent and flavor and aroma composition containing the same |
| CN102370857A (en) * | 2010-08-27 | 2012-03-14 | 翟长民 | Rhinitis treating paste |
| CN102648934A (en) * | 2011-02-24 | 2012-08-29 | 邴守兰 | Traditional Chinese medicine composition for treating chronic simple rhinitis and preparation method thereof |
| WO2016019627A1 (en) * | 2014-08-08 | 2016-02-11 | Shenzhen Hightide Biopharmaceutical, Ltd. | Liquid formulation compositions, medicament delivery devices, and methods of preparation and use thereof |
| CN104840520A (en) * | 2015-03-30 | 2015-08-19 | 李志君 | Rhinitis oil formula and preparation technology thereof |
| CN104940727A (en) * | 2015-07-07 | 2015-09-30 | 王睿超 | Paste for treating rhinitis and preparation method thereof |
| CN107569536A (en) * | 2017-09-22 | 2018-01-12 | 杨斌 | A kind of rhinitis paste and preparation method thereof |
| CN108096308A (en) * | 2018-01-23 | 2018-06-01 | 袁影丽 | A kind of drug for treating allergic rhinitis, preparation and preparation method thereof |
| CN110652544A (en) * | 2019-11-20 | 2020-01-07 | 吴波 | Pharmaceutical composition for treating rhinitis and preparation method thereof |
Non-Patent Citations (3)
| Title |
|---|
| 尹智星;李德莹;苏惠萍;: "冬病夏治临床应用文献研究" * |
| 白安福;白平;任庆涛;白安芳;: "自拟"鼻炎滴剂治疗慢性鼻炎、鼻窦炎"200例疗效观察" * |
| 陈小欢;郭佳华;黄春连;: "马应龙麝香痔疮膏治疗大便失禁患者肛周皮肤破损效果的观察及护理" * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Rachelefsky et al. | Chronic sinus disease with associated reactive airway disease in children | |
| CN103301254B (en) | Antibacterial liquid used for nasopharyal meatus and preparation method thereof | |
| Lyons | The treatment of staphylococcal cavernous sinus thrombophlebitis with heparin and chemotherapy | |
| CN108743776A (en) | A kind of flushing powder for nasal disease prevention | |
| CN111603485A (en) | Medicine formula for treating rhinitis and preparation method | |
| Satdhabudha et al. | A randomized controlled study comparing the efficacy of nasal saline irrigation devices in children with acute rhinosinusitis | |
| CN105012487B (en) | Children's nose, which relaxes, leads to nasal drops | |
| Krasno et al. | Inhalation of penicillin dust | |
| CN103877288B (en) | A kind of chitosan nasopharynx biological medicinal membrane and preparation method thereof | |
| BOSWORTH et al. | Streptomycin in tuberculous bone and joint lesions with mixed infection and sinuses | |
| CN115414325A (en) | Nano-silver nasal cavity nursing and sterilizing solution and preparation method and application thereof | |
| CN100415244C (en) | Nasal drip liquor for treating rhinitis and nasosinusitis | |
| Hopkins | Medical Management For Rhinosinusitis | |
| CN102940882B (en) | Medicine for treating respiratory diseases | |
| Kholboevich | ACUTE SINUSITIS: MODERN PRINCIPLES OF ANTIBIOTIC THERAPY | |
| CN108434203A (en) | A kind of Chinese medicine ointment and its preparation method and application for treating nasal polyp | |
| Myall et al. | Chronic factitious illness: recognition and management of deception | |
| CN102784161A (en) | Specific ear drops for treating acute/chronic tympanitis | |
| Liu et al. | Wrist–ankle acupuncture combined with pinching along the spine for children allergic rhinitis: A randomized controlled trial | |
| CN101978968B (en) | Medicament for treating tympanitis | |
| Goodner | Routine preoperative and postsurgical management | |
| Tremble et al. | Nasal Medication in Sinusitis | |
| Sanghera et al. | Is capsaicin an effective treatment of nonallergic rhinitis? | |
| Jokar et al. | Effectiveness of Prophylactic Antibiotics in Infection Prevention in Closed Lower-Limb Fracture Surgery | |
| Toh et al. | Severe tetanus in a patient with ulcerating inflammatory breast carcinoma: A case report and review of management |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200901 |
|
| RJ01 | Rejection of invention patent application after publication |